Despite the fact that the primary endpoint did not reach statistical significance, the results indicate that the optimal dose is 10 μM trabedersen, as both efficacy (tumor control rate, tumor progression rate, and survival rate) and safety results tended to be superior for the 10 μM dose compared with the 80 μM dose, despite the inferior prognosis (higher age and tumor volume) of the 10 μM group at baseline.
← all excerpts
Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study.
1
—
—